Lupin gets USFDA’s observations for Nagpur Unit-2 facility

31 Oct 2022 Evaluate

The USFDA has inspected Lupin’s Nagpur Unit-2 injectable manufacturing facility from October 17, 2022 to October 29, 2022. The inspection was a Pre-Approval Inspection of the injectable facility.

The inspection closed with issuance of a Form-483 with five observations. The company is committed to addressing the observations at the earliest, and gaining approval for injectable manufacturing for the U.S.

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2195.00 18.20 (0.84%)
14-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1700.55
Dr. Reddys Lab 1186.45
Cipla 1434.60
Zydus Lifesciences 884.00
Lupin 2195.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×